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The sympathetic nervous system (SNS) regulates host defense responses and restores
homeostasis. SNS-immune regulation is altered in rheumatoid arthritis (RA) and rodent
models of RA, characterized by nerve remodeling in immune organs and defective adren-
ergic receptor (AR) signaling to immune cell targets. The SNS typically promotes or
suppresses inflammation via α- and β2-AR activation, respectively, and indirectly drives
humoral immunity by blocking Th1 cytokine secretion. Here, we investigate how β2-AR
stimulation and/or α-AR blockade at disease onset affects disease pathology and cytokine
profiles in relevant immune organs from male Lewis rats with adjuvant-induced arthritis
(AA). Rats challenged to induce AA were treated with terbutaline (TERB), a β2-AR agonist
(600µg/kg/day) and/or phentolamine (PHEN), an α-AR antagonist (5.0 mg/kg/day) or vehicle
from disease onset through severe disease. We report that in spleen, mesenteric (MLN)
and draining lymph node (DLN) cells, TERB reduces proliferation, an effect independent of
IL-2. TERB also fails to shift T helper (Th) cytokines from a Th1 to Th2 profile in spleen and
MLN (no effect on IFN-γ) and DLN (greater IFN-γ) cells. In splenocytes, TERB, PHEN, and
co-treatment (PT) promotes an anti-inflammatory profile (greater IL-10) and lowers TNF-α
(PT only). In DLN cells, drug treatments do not affect inflammatory profiles, except PT,
which raised IL-10. In MLN cells, TERB or PHEN lowers MLN cell secretion of TNF-α or IL-
10, respectively. Collectively, our findings indicate disrupted β2-AR, but not α-AR signaling
in AA. Aberrant β2-AR signaling consequently derails the sympathetic regulation of lym-
phocyte expansion, Th cell differentiation, and inflammation in the spleen, DLNs and MLs
that is required for immune system homeostasis. Importantly, this study provides potential
mechanisms through which reestablished balance between α- and β2-AR function in the
immune system ameliorates inflammation and joint destruction in AA.
Keywords: sympathetic nervous system, rheumatoid arthritis, macrophage,T cell, cytokine balance, spleen, lymph
nodes, peripheral blood mononuclear cells
INTRODUCTION
Autonomic and immune dysfunction, and dysregulation of their
cross-communication in autoimmune diseases, are hallmarks of
many autoimmune diseases, including rheumatoid arthritis (RA)
(1–4). In RA, chronic inflammation, “self” targeted arthritogenic
T cells and autoantibodies drive the damage in the affected joints
and visceral organs (5). Thus, altered innate and adaptive immu-
nity are key mediators of the disease process (5, 6). Dysregula-
tion of the immune system is coupled with hyperactivity of the
sympathetic nervous system (SNS). Dysregulation of the SNS
in the immune system contributes significantly to disease onset,
and greater severity in RA and experimentally-induced arthritis
(7, 8). The contribution of a dysregulated SNS and the altered
cross-communication between SNS and the immune system in
autoimmune diseases is complex. In adjuvant- and collagen-
induced arthritis models [adjuvant-induced arthritis (AA) and
CIA, respectively], the SNS exerts a pro-inflammatory influence
during the inductive, asymptomatic phase, but suppresses the
inflammatory and cell-mediated response after disease onset (9,
10). Thus, we still do not understand the complex and diverse roles
of the SNS in regulating innate and adaptive immunity that medi-
ate rheumatic disease mechanisms prior to and after disease onset.
Growing evidence indicates that the SNS is an important target for
developing disease amelioration, or even preventing disease onset,
supporting the need to understand sympathetic-immune system
cross-talk in RA (2).
We have shown disease promoting effects of sympathetic inner-
vation of secondary lymphoid organs during the induction phase,
a time of antigen processing, and disease enhancing effects in the
effector phase of AA (11, 12). This finding was subsequently con-
firmed using the collagen-induced arthritis model of RA (13).
In these studies, sympathetic nerves were destroyed by selective
toxins (11, 13) or β2-adrenergic receptor (AR) agonist and/or
α-AR antagonist treatment (12) prior to the autoimmune induc-
ing challenge or after disease onset. Treatment with a β2-AR
agonist and/or α-AR antagonist shifts the balance of pro- and
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anti-inflammatory cytokine production toward increased disease
severity if administered prior to or reduced disease activity after
disease onset, respectively. These findings indicate that changes
in the nerves and receptors contribute to the opposite disease
outcome effects of the SNS observed after challenge and disease
onset. Consistent with this notion, we (14–16) and others (17)
previously reported dramatic changes in the density and distribu-
tion of sympathetic nerves to discrete compartments in secondary
immune organs in rodent models of RA, and in the affected joints
of RA patients. These anatomical changes suggest that sympathetic
nerves interact with various immune cell populations in different
activational states and functional compartments. They also impli-
cate a link between consequent changes in sympathetic-immune
cell signaling with disease development and progression.
The SNS regulates the functions of immune cells that medi-
ate rheumatic disease through the activation of α- and β2-ARs
expressed on their cell surfaces (10, 17–19). Sympathetic nerves
target immune cells in secondary lymphoid organs (15, 16), and
the immune cell infiltrates and tertiary lymph nodules that occur
in the affected joints (20). In secondary lymphoid organs, neuro-
transmitters, predominantly norepinephrine released from sym-
pathetic nerves, activate β2-ARs expressed in T cells to inhibit
IL-2 production, which subsequently suppresses lymphocyte pro-
liferation required for clonal expansion [reviewed in Ref. (21)].
Activation of β2-ARs also inhibit cellular and promote humoral
immunity by regulating the phenotypic differentiation of CD4+
T helper (Th) cells in response to challenge with T-cell-dependent
antigens (21). This occurs by norepinephrine activating Th0/Th1
cell β2-ARs, which increase intracellular cAMP production. Cyclic
AMP then inhibits IFN-γ production. The decrease in IFN-γ
reduces the inhibitory cross-regulation of IFN-γ on IL-4 produc-
tion, thus promoting IL-4 synthesis by Th2 cells. In this man-
ner, the SNS provides a negative feedback mechanism to restore
immune system homeostasis after antigen challenges that activate
cellular immunity (21).
Recently, we found that activation of β2-ARs no longer induces
cAMP in immune cells in the spleen and lymph nodes that
drain the arthritic hind-limbs in AA during severe disease (18).
Altered β2-AR responses occurred concomitantly with altered
receptor-ligand affinity and lymphoid tissue changes in receptor
phosphorylation. These findings predict that a negative feed-
back mechanism required to restore immune system homeostasis
after adjuvant challenge is lost after disease onset. However, the
impact of sympathetic regulation of IL-2, IFN-γ, and IL-4 pro-
duction in disease-relevant secondary lymphoid organs has not
been determined.
The SNS also time-dependently regulates pro- and anti-
inflammatory cytokine production relative to the antigen chal-
lenge [reviewed in Ref. (21)]. After antigen challenge, norepi-
nephrine released from sympathetic nerves at the site of chal-
lenge promotes TNF-α and suppresses IL-10 production by acti-
vating α-ARs expressed in macrophages to amplify the ensu-
ing inflammatory response. Similarly, norepinephrine promotes
TNF-α and suppresses IL-10 production in dendritic cells from
secondary lymphoid tissue via α-ARs. In contrast, activation of
β2-AR in macrophages and dendritic cells suppresses TNF-α and
promotes IL-10 production. The balance between the anti- and
pro-inflammatory effects of the SNS is dependent upon the bal-
ance between α- and β2-AR expression, intracellular signaling
pathways they activate and the dynamic local environment that
follows the arthritis inducing challenge (9, 12). In this manner,
the SNS regulates the initiating and shutting off of inflamma-
tory and innate immune responses. In animal models of RA,
α-AR antagonists and β2-AR agonists promote or inhibit joint
inflammation if administered prior to or after disease onset,
respectively. The effects of altered sympathetic innervation and
changes in β2-AR function on SNS regulation of pro- and anti-
inflammatory cytokines seen previously in secondary lymphoid
organs of arthritic rats have not been examined.
The purpose of this study was to determine how the SNS affects
ex vivo cytokine production in secondary lymphoid organs during
the effector phase of disease. Specifically, we examined the effect
of AR selective drug treatments in (1) modulating IL-2 and prolif-
eration, and (2) the balance between IFN-γ and IL-4 and between
TNF-α and IL-10 after AA development. A specific β2-AR agonist
and an α-AR antagonist, alone and in combination [previously
designated SH1293 (12)] were administered in vivo after disease
onset. These treatments were used to determine the contribution
of each receptor subtype in altering cytokine production and dis-
ease outcome. T cell and macrophage cytokines were measured ex
vivo for each tissue collected from each treatment group. Cytokines
with crucial roles in Th cell differentiation and clonal expansion
or inflammation were selected for assessment: (1) immune cell
production of IL-2, an important cytokine for development and
differentiation of Th cells and proliferative responses required for
clonal expansion (22); (2) IL-4 and IL-10, cytokines, which pro-
mote Th2 cell development and have anti-inflammatory functions;
(3) IFN-γ and TNF-α, which promote Th1 cell development and
which drive inflammation (23, 24).
MATERIALS AND METHODS
SUPPLIES, DRUGS, AND ADJUVANT PREPARATION
All tissue culture media and supplements were obtained from
Gibco BRL (Rockville, MD, USA) unless otherwise stated. OPTIA
sandwich ELISA kits for IL-2, IL-4, IL-10, IFN-γ, and TNF-α were
purchased from BD Pharmingen (San Diego, CA, USA). The non-
specific α-AR antagonist, phentolamine, and the β2-AR agonist,
terbutaline, were obtained from Sigma Chemical Company (St.
Louis, MO, USA). All adrenergic drugs were dissolved in 0.01 mM
ascorbic acid in 0.9% sterile, endotoxin-free saline. Complete Fre-
und’s adjuvant (CFA; 0.03 g dried and heat-killed Mycobacterium
butyricum; Difco, Detroit, MI, USA) was emulsified in 10 ml ster-
ile mineral oil, as previously described (18). The suspension was
treated with a sonic dismembraner for 5 min to keep the bacterial
cell wall in suspension for animal injections. A single preparation
of CFA was used to minimize variability, and 100% of the animals
developed arthritis.
ANIMALS
Male Lewis rats (200–250 g) were obtained from Charles River
Laboratories (Raleigh, NC, USA) and housed two per cage for
3 weeks prior to the start of each experiment. The animals were
maintained on a 12-h off/on light schedule, and food (Purina Lab
Diet 5001) and water were available ad libitum. For AA rats, the
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food was placed in the bottom of the cage, and water was supplied
using long-stemmed sipper tubes. All rats were observed to eat
and drink throughout the study period. Animals were weighed
biweekly to monitor adequate weight gain. All animals were treated
in the same manner. Other than the development of arthritis, rats
were healthy throughout the experiment. All protocols for the use
and care of the animals in the study were approved by our Animal
Use and Care Committee, and complied with NIH guidelines for
the humane use and care of research animals.
Thirty-two male Lewis rats were given 100µl of CFA by intra-
dermal injection into the base of the tail. Twelve days later, rats
were randomly assigned to one of four groups (N = 8 per group):
(1) phentolamine [PHEN; 125µg/day intraperitoneal (i.p.)]; (2)
terbutaline [TERB; 1200µg/day (i.p.)]; (3) phentolamine and
terbutaline (PT, same dose as PHEN and TERB); or (4) vehi-
cle (VEH). Drug treatment was divided into two injections in
a total volume of 250µl per injection given at 7 a.m. and 6 p.m.,
as previously described (12). This treatment regimen was based
on previous reports demonstrating predictable pharmacological
effects on disease severity in arthritic rats (9, 12). Adrenergic ther-
apies began 12 days after immunization, the time of disease onset,
and continued until sacrifice. All animals were weighed prior
to sacrifice on day 28 using an overdose of 8% chloral hydrate
10.0 ml/kg body weight.
At sacrifice, the inguinal and popliteal lymph nodes (DLN,
lymph nodes that drain the site of antigen challenge), mesenteric
lymph nodes (MLN), and spleen were dissected and weighed, and
peripheral blood was collected. Cell suspensions from all immune
tissues were prepared for cell culture. All methods used in this
study have been previously described in detail (12, 18). Non-
arthritic animals were not included in this study, but reference
ranges from non-arthritic rats from our database are shown as
light gray horizontal bars to indicate normal values or non-specific
activity, as appropriate.
ASSESSMENT OF DISEASE OUTCOME
The inflammatory response in the arthritic rats was assessed
by routine methods previously described (12, 18). Dorsoplantar
widths of the hind feet were measured using a Mitutoyo Corpora-
tion dial thickness gage on the day of sacrifice. Prior to sacrifice,
radiographs of the hind-limbs were taken to assess disease sever-
ity. Radiographs were taken using the following settings: 400 nN,
50 kVp, 0.4 s exposure time at 40 cm, using an X-OMAT proces-
sor. Using a grading scale modified from Ackerman and coworkers
(25), the radiographs were coded to obscure the treatment groups,
then two independent observers subjectively rated each of the
radiographs on the scale: 0 (normal), 1 (slight), 2 (mild), 3 (mod-
erate), and 4 (severe) abnormalities in the tissue. The radiographs
were scored for each of the following characteristics: (1) soft tissue
swelling as indicated by the width of soft tissue shadows and alter-
ations in the normal configuration of the soft tissue planes; (2)
osteoporosis (recognized by increases in radiolucency relative to
uninvolved adjacent bone); (3) cartilage loss shown by narrowing
of the joint spaces; (4) heterotopic ossification defined as prolif-
eration of new bone tissue (fine ossified line paralleling normal
bone, but not contiguous with calcified area of the bone itself);
and (5) bone erosions. The radiographic scores for each category
were added for both hind-limbs giving a maximum score of 40.
IMMUNE CELL CULTURES
Spleens were placed in a stomacher bag and homogenized in
Hank’s balanced salt solution (HBSS) for 30 s. Spleen cells were
washed with HBSS, and passed through a nylon mesh (Fisher
Scientific, St Louis, MO, USA) to remove the connective tissue.
Spleen cells were centrifuged and the pellet was resuspended in
5 ml NH4Cl hypotonic buffer for 3 min to lyse red blood cells. The
cells were washed 2× with 10 ml HBSS, centrifuged, and resus-
pended in complete RPMI 1640 media (Gibco BRL, Rockville,
MD, USA) supplemented with 5% fetal calf serum and 1% antibi-
otic/antimycotic (complete media). Using forceps, MLNs and
DLNs were teased apart in HBSS. Each homogenate was passed
through a nylon mesh, washed in 5 ml HBSS, centrifuged, and
resuspended into complete media, as described above. Lymph
node and spleen cells were counted using a hemocytometer and
adjusted to 2× 106 cells/ml in complete media.
Blood was collected using cardiac puncture into 7-ml lithium
heparin vacutainer tubes. After tube inversion (7×), blood cells
were pelleted at 1,000 rpm for 15 min at 10°C. The buffy coat
was removed and placed into 10 ml NH4Cl hypotonic buffer for
3 min to lyse red blood cells. Peripheral blood mononuclear cells
(PBMCs) were centrifuged, and the cell pellet was resuspended and
washed 3× in 10 ml HBSS. Following the last centrifugation, the
cells were resuspended in complete media. PBMCs were counted
and suspended at 2× 106 cells/ml in complete media. In this study,
additional immune challenge was omitted to better mimic in vivo
disease conditions.
EX VIVO CELLULAR PROLIFERATION
Immune cells in supplemented complete RPMI 1640 were plated
in 96-well, flat-bottom plates (Falcon, Oxnard, CA, USA) at
2× 105 cells/well in triplicate without further stimulation. In this
study, additional immune challenge was omitted to better mimic
in vivo disease conditions. Cultures were maintained for 72 h
in a humidified, 7% CO2 incubator at 37°C. [3H]Thymidine
(0.5µCi/10µl; Amersham,Arlington Heights, IL, USA) was added
the last 24 h of culture. Cells were harvested onto glass fiber
filters (Brandel, Gaithersburg, MD, USA) using a cell harvester
(Brandel, Gaithersburg, MD, USA). The filters were placed in
5 ml of scintillation fluid (Fisher Scientific, Tustin, CA, USA),
and [3H]Thymidine incorporation was determined using a liquid
scintillation counter (Beckman, Brea, CA, USA).
CYTOKINE PRODUCTION
Two milliliters of each cell suspension were plated into 24-well
plates (Falcon, Oxnard, CA, USA), and incubated in 7% CO2 at
37°C for 24 h. After 24 h, the supernatants were harvested and
stored at−80°C. Cytokine ELISAs were run according to the man-
ufacturer’s instructions. Cytokine levels in unknown samples were
determined through comparison with a standard curve obtained
from known concentrations of the cytokines run in duplicate on
each plate using a Ceres 900 HDI plate reader at 450 nm (Bio Tek
Instruments Incorporated, Winooski, VT, USA).
STATISTICAL ANALYSIS
All data are expressed as a mean± standard error of the mean
(SEM), unless otherwise stated. For disease outcome measure-
ments the right and left footpads from each animal were averaged,
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and the individual means per group determined (mean of a mean
in millimeters). Group differences were determined by two-way
ANOVA with repeated measures. Means found to be significantly
different (p< 0.05) were subjected to Bonferroni post hoc analy-
ses. Mean radiograph scores from two scorers completed without
knowledge of the treatment group were averaged for each group,
and then subjected to Kruskal–Wallis statistical analysis with Dunn
post hoc testing. Body and spleen weights were averaged for each
treatment group (mean expressed in grams).
For cell proliferation, counts from triplicate wells were aver-
aged after subtraction of background radioactivity. Group means
were determined,and data were expressed as [3H]thymidine incor-
poration in counts per minute (cpm). Cytokine concentrations
from duplicate wells were averaged, group means were calculated,
and the data expressed as a mean in picograms per milliliter. The
individual cytokine and the cytokine ratios were determined for
each animal by comparing the samples to the standard curve on
each plate. Group differences in body and spleen weights, cytokine
production, cytokine ratios, and cellular proliferation were deter-
mined by one-way ANOVA. Means found to be significantly
different (p< 0.05) were subjected to Bonferroni post hoc analyses.
RESULTS
ADRENERGIC DRUGS ATTENUATED INFLAMMATION AND BONE LOSS
Footpad widths and X-ray scores from drug- and VEH-treated rats
are presented in Figures 1A,B, respectively. All adrenergic inter-
ventions significantly reduced the dorsoplantar footpad width
compared with VEH-treated arthritic rats (p< 0.001) (Figure 1A).
All arthritic rats had greater footpad widths compared with non-
AA rats (normal range indicated by the gray horizontal bar shown
in Figure 1A). There was also a dramatic reduction in the radi-
ographic scores from the arthritic rats treated with TERB com-
pared with VEH-treated arthritic rats (Figure 1B; pTERB< 0.05,
pPHEN< 0.05, or pPT< 0.01). X-rays of ankle joints from VEH-
treated arthritic rats showed greater soft tissue swelling and
joint destruction compared with arthritic rats treated with TERB,
PHEN, or PT (Figures 1D–H). These observations were confirmed
with X-ray analysis (Figure 1C). Figure 1C demonstrates the
adrenergic drug-induced reduction in the components that com-
prise the radiographic scores. Adrenergic drug treatments reduced
periosteal bone formation (POBF) 260–490%, bone erosions 170–
270%, osteoporosis 190–320%, cartilage loss (JT NR) 140–220%,
and soft tissue swelling 140–290% compared with VEH-treated
arthritic animals. The rank order of potency for reducing soft
tissue swelling and lower X-ray scores for the treatments was
PT>TERB=PHEN>VEH.
ADRENERGIC DRUGS PREVENTED LOSS OF BODY WEIGHT AND
INCREASED SPLEEN WEIGHT
Between day 8 and 12 post-CFA challenge, there was a sharp
decline in body weight (~10–15%) that leveled off between days 12
and 16, and then was maintained through the effector phase of the
disease (data not shown). In rats treated with TERB and PT, weight
loss was prevented compared with VEH-treated control animals at
day 28 post-CFA challenge (Figure 1I, p< 0.01). There was a trend
(p< 0.1) toward weight loss prevention in rats treated with PHEN.
Additionally, disease development resulted in greater spleen
weights compared with the normal range (light gray horizontal
bar; p< 0.001; Figure 1J). Combined drug treatment, PT, partially
reversed the disease-induced increase in spleen mass compared
with the VEH-treated AA rats (p< 0.05); however, the PT-treated
animals still had spleens with significantly greater mass than the
non-arthritic controls (light gray horizontal bar; p< 0.05).
NO EFFECTS OF ADRENERGIC DRUGS ON PBMC PROLIFERATION
DESPITE LOWER IL-2 PRODUCTION BY α-AR BLOCKADE
On day 28 post-CFA challenge, the proliferative activity of PBMCs
from arthritic rats (Figure 2A) was low in all the treatment
groups (~130–200 cpm), but was slightly higher than the level
seen in untreated PBMCs from non-AA rats (light gray horizontal
bar). There were no differences in PBMC proliferation among the
drug treatment groups or when compared with VEH treatment.
Despite the absence of drug-induced effects on PBMC proliferative
responses, ex vivo IL-2 production was affected by drug treatment
on day 28 post-CFA challenge (Figure 2B). PBMCs from VEH-
and TERB-treated arthritic rats released relatively similar levels of
IL-2 (Figure 2B). Unlike TERB, IL-2 concentration was reduced in
both PHEN- (p< 0.01) and PT- (p< 0.01) treated PBMC cultures
compared with VEH-treated AA controls.
α-AR ADRENERGIC THERAPIES REDUCED PBMC Th1 AND
PRO-INFLAMMATORY CYTOKINE PRODUCTION
In ex vivo cultures of PBMCs from all treatment groups, IL-4
concentrations were similar (Figure 3A). PBMCs from VEH-
treated arthritic rats secreted more IFN-γ (319± 76 pg/ml)
(Figure 3B) compared with IL-2 (103± 15 pg/ml, Figure 2B) and
IL-4 (49± 11 pg/ml, Figure 3A). Treatment with TERB alone did
not affect IFN-γ secretion. However, PHEN and PT significantly
reduced the IFN-γ concentration compared with VEH- or TERB-
treated AA rats (PHEN vs. VEH or TERB, p< 0.01; PT vs. VEH or
TERB, p< 0.05).
PBMCs from VEH-treated arthritic rats secreted low levels of
TNF-α (123± 21 pg/ml) (Figure 3C) and IL-10 (28± 5 pg/ml)
(Figure 3D). There was no difference in TNF-α production in
TERB- or VEH-treated arthritic rats (Figure 3C). However, PHEN
treatment showed a trend (p< 0.1) toward reduced TNF-α pro-
duction compared with VEH-treated arthritic rats (Figure 3C)
and PT treatment significantly inhibited TNF-α release compared
with VEH- or TERB-treated arthritic rats (p< 0.05) (Figure 3C).
Treatment with TERB, PHEN, or PT had no effects on IL-10 con-
centration compared with VEH-treated arthritic rats (Figure 3D).
ADRENERGIC THERAPIES REDUCED EX VIVO SPLEEN CELL
PROLIFERATIVE RESPONSE AND DIFFERENTIALLY AFFECTED IL-2
PRODUCTION
Thymidine incorporation was greater in the spleen cells from
VEH-treated arthritic than untreated non-arthritic rats (light gray
horizontal bar; Figure 4A). Splenocyte proliferation was 28-fold
greater than PBMC proliferation (Figure 2A). In vivo treatment
with TERB, PHEN, or PT markedly reduced spleen cell prolifera-
tion compared with VEH treatment (Figure 4A; p< 0.001). IL-2
levels were low (28± 5 pg/ml), but detectable in the VEH-treated
arthritic animals (Figure 4B). Despite the drug-induced suppres-
sion in proliferation (Figure 4A), IL-2 concentrations (Figure 4B)
were no different in cultures from TERB- or PT-treated rats, and
elevated in cultures from PHEN-treated rats compared with VEH
treatment (p< 0.05).
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FIGURE 1 | Indices of disease severity. Animals were treated with
twice-daily i.p. injections of vehicle (VEH, black bars), terbutaline (TERB),
phentolamine (PHEN), or phentolamine and terbutaline (PT) initiated 12 days
after adjuvant challenge. (A) Mean Footpad widths±SEM were significantly
reduced in TERB (white bar), PHEN (dark gray bar), and PT (light gray bar)
treated compared with VEH (black bar) treated rats. Light gray horizontal bar
represents the mean footpad width±SEM of naïve rat. N =8. ***p<0.001.
(B) Mean radiographic scores±SEM for, AA rats treated with TERB (white
bar), PHEN (dark gray bar), and PT (light gray bar) were decreased compared
with VEH (black bar). N =8. *p<0.05; **p< 0.01. (C) Stack-plots showing the
contribution of each radiographic score component to the mean total
radiographic score for rats treated with VEH, TERB, PHEN, or PT. Swelling,
blue; joint narrowing (JT NR), red; osteoporosis, green; bone loss, purple;
periosteal bone formation (POBF), turquoise. (D) Radiograph of the hind limb
representative of normal untreated rats. (E) Radiograph of the hind limb
representative of vehicle (VEH)-treated rats. (F) Radiograph of the hind limb
representative TERB-treated rats. (G) Radiograph of the hind limb
representative of PHEN-treated rats. (H) Radiograph of the hind limb
representative of PT-treated rats. (I) Mean body weights in grams (g) ±SEM
for rats treated with vehicle (VEH), terbutaline (TERB), phentolamine (PHEN),
or phentolamine and terbutaline (PT). The light gray bar represents the range
of body weights for untreated non-arthritic rats. N =8. **p<0.01. (J) Mean
spleen weights in grams (g) ±SEM for rats challenged with adjuvant and
treated with vehicle (VEH) or phentolamine and terbutaline (PT). The light gray
bar represents the range for normal spleen weights of untreated non-arthritic
rats. N =8. *p<0.05.
FIGURE 2 | Proliferative response and IL-2 production in peripheral blood
mononuclear cells (PBMC). Animals were treated with twice-daily i.p.
injections of vehicle (VEH, black bars), terbutaline (TERB, white bars),
phentolamine (PHEN, dark gray bars), or phentolamine and terbutaline (PT,
light gray bars) initiated 12 days after adjuvant challenge. (A) Proliferative
responses 72 h post-PBMC cell culture did not differ between treatment
groups. N =8. Gray horizontal bar represents the range for 3H-thymidine
incorporation in unstimulated PBMCs. (B) IL-2 production 24 h-post PBMC
culture were reduced in PHEN- and PT-treated compared with VEH-treated AA
rats. N =8. All data represent means±SEM. **p<0.01.
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FIGURE 3 | Cytokine production in peripheral blood mononuclear
cells (PBMC). Animals were treated with twice-daily i.p. injections of
vehicle (VEH, black bars), terbutaline (TERB, white bars), phentolamine
(PHEN, dark gray bars), or phentolamine and terbutaline (PT, light gray
bars) initiated 12 days after adjuvant challenge. (A) IL-4 concentrations
24 h after PBMC culture did not differ among the treatment groups.
N =8. (B) IFN-γ production 24 h post-PBMC culture was reduced by
either PHEN or PT compared with VEH treatment. N =8. *p<0.05;
**p<0.01. (C)TNF-α secretion from PBMCs was reduced by PT
compared with VEH treatment 24 h post-culture. N =8. *p<0.05.
(D) IL-10 production in PBMCs was similar in all treatment groups after
24 h of cell culture. N =8.
FIGURE 4 | Ex vivo proliferation and IL-2 production by spleen (SPL)
cells 72 and 24h post-culture, respectively. Animals were treated with
twice-daily i.p. injections of vehicle (VEH, black bars), terbutaline (TERB,
white bars), phentolamine (PHEN, dark gray bars), or phentolamine and
terbutaline (PT, light gray bars) initiated 12 days after adjuvant challenge.
(A) 3H-Thymidine incorporation into spleen cells was significantly lower in
all drug-treated groups compared with VEH controls. The horizontal light
gray bar represents the range of non-specific background in untreated
non-arthritic rats. N =8. ***p< 0.001. (B) IL-2 secreted by spleen cells
was greater with PHEN compared with VEH treatment, but IL-2
concentrations in the other treatments did not differ from VEH-treated
rats. N =8. *p<0.05.
ADRENERGIC THERAPY REDUCED EX VIVO PRO-INFLAMMATORY AND
INCREASED Th2 CYTOKINE PRODUCTION IN SPLEEN CELLS
Figures 5A–D show the ex vivo secretion of IL-4 (Figure 5A), IFN-
γ (Figure 5B), TNF-α (Figure 5C), and IL-10 (Figure 5D). There
was no effect of any of the drug treatments on IL-4 or IFN-γ pro-
duction compared with VEH controls (Figures 5A–B). Treatment
with PT significantly reduced TNF-α production by spleen cells
compared with VEH-treated arthritic rats (Figure 5C; p< 0.01).
Spleen cells from rats receiving PHEN tended to produce less
TNF-α than rats treated with VEH (p< 0.1), while TERB had no
effect compared to VEH treatment. Spleen cells from VEH-treated
arthritic rats secreted ~4-fold more IL-10 (Figure 5D) compared
with PBMCs (Figure 3D). Interestingly, TERB, PHEN, or PT
treatment markedly enhanced splenocyte IL-10 production com-
pared with VEH-treated arthritic rats (Figure 5D; pTERB< 0.05;
pPHEN< 0.05; pPT< 0.01). There were no significant differences
in splenocyte IL-10 production between any of the adrenergic
drug-treated animals.
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ADRENERGIC THERAPIES SUPPRESSED EX VIVO CELL PROLIFERATION
IN DLN, BUT DIFFERENTIALLY AFFECTED IL-2 PRODUCTION
Proliferative responses of DLN cells from VEH-treated arthritic
animals were elevated compared with DLN cells from non-
arthritic rats (light gray horizontal bars; Figure 6A). Additionally,
DLN cell proliferation in VEH-treated rats was reduced 1.5-fold
compared with the spleen (Figure 4A), but 19- or 6.7-fold higher
than for PBMCs (Figure 2A) or MLN cells (Figure 8A), respec-
tively. In vivo treatment with TERB, PHEN, or PT dramatically
(>600%) reduced DLN cell proliferation compared with the VEH-
treated arthritic animals (Figure 6A; p< 0.001). In VEH-treated
arthritic rats, IL-2 concentrations from DLN cell cultures were
similar to spleen cell cultures (Figure 6B), and much lower than
PBMC cell cultures (Figure 4B). Treatment with TERB or PHEN
tended to increase IL-2 concentrations (p< 0.1; Figure 6B), but PT
treatment significantly elevated IL-2 production compared with
DLN cells from VEH-treated arthritic rats (p< 0.05) (Figure 6B).
ADRENERGIC INTERVENTIONS DIFFERENTIALLY AFFECTED EX VIVO
CYTOKINE SECRETION IN DLN CELLS
In vivo administration of PT significantly increased IL-4 levels
over levels in VEH-treated arthritic rats (Figure 7A; p< 0.05),
but there was no effect of TERB or PHEN treatment on IL-
4 concentrations. Interestingly, TERB and PT, but not PHEN,
increased IFN-γ production in DLN cells compared with VEH
treatment (pTERB< 0.05; pPT< 0.01) (Figure 7B). In contrast,
none of the adrenergic treatments altered TNF-α production in
DLN cells compared with VEH-treated arthritic rats (Figure 7C).
PT treatment significantly increased the IL-10 concentration com-
pared with VEH-treated arthritic rats (pPT< 0.05) (Figure 7D),
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FIGURE 5 | Cytokine production by spleen (SPL) cells after 24h
of culture. Animals were treated with twice-daily i.p. injections of
vehicle (VEH, black bars), terbutaline (TERB, white bars),
phentolamine (PHEN, dark gray bars), or phentolamine and
terbutaline (PT, light gray bars) initiated 12 days after adjuvant
challenge. (A) IL-4 production. N =8. (B) IFN-γ levels. N =8.
(C)TNF-α secretion. N =8. **p<0.01. (D) IL-10 release. N =8.
*p<0.05; **p<0.001.
FIGURE 6 | Proliferation of draining lymph node (DLN) cells and IL-2
production. Animals were treated with twice-daily i.p. injections of vehicle
(VEH, black bars), terbutaline (TERB, white bars), phentolamine (PHEN, dark
gray bars), or phentolamine and terbutaline (PT, light gray bars) initiated
12 days after adjuvant challenge. (A) All drug treatments suppressed
proliferation of DLN cells compared with VEH treatment. Horizontal light gray
bar demonstrates non-specific background. (B) IL-2 production by DLN cells is
elevated in PT compared with VEH treatment. N =8. *p<0.5; **p<0.01.
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but treatment with TERB or PHEN had no effect compared with
VEH-treated arthritic rats.
ADRENERGIC THERAPIES SUPPRESSED PROLIFERATION IN MLN CELLS
WITHOUT AFFECTING IL-2 PRODUCTION
Thymidine incorporation by MLN cells was greater for all treat-
ment groups than unstimulated non-arthritic rats (indicated by
gray horizontal bars; Figure 8A). Drug-treated MLN cultures
had lower cell proliferation (>600%) than VEH-treated rats
(p< 0.001). Proliferative responses in MLN (Figure 8A) were 10-
fold lower than observed for spleen (Figure 4A), but 2.8-fold
greater than observed for the PBMCs (Figure 2A). IL-2 pro-
duction was low, with no differences between treatment groups
(Figure 8B).
ADRENERGIC TREATMENT-INDUCED SUPPRESSION OF
PRO-INFLAMMATORY AND Th CYTOKINE PRODUCTION IN CULTURED
MLN CELLS
There were no significant effects of any of the drug treatments
on IL-4 concentrations in MLN cell cultures compared with VEH
treatment (Figure 9A). IL-4 concentrations from MLN cell cul-
tures were similar to levels observed in spleen (Figure 5A), but
almost double values observed in PBMC or DLN cell cultures
(Figures 3A and 7A, respectively). In vivo treatment with TERB
or PHEN alone had no effect on the IFN-γ production in MLN
cells compared with the VEH-treated arthritic rats (Figure 9B).
However, PT treatment significantly reduced IFN-γ production
compared with VEH-treated arthritic rats (p< 0.05). TERB and
PT treatment reduced TNF-α production compared with VEH
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FIGURE 7 | Cytokine production by draining lymph node (DLN) cells after
24h of culture. Animals were treated with twice-daily i.p. injections of
vehicle (VEH, black bars), terbutaline (TERB, white bars), phentolamine
(PHEN, dark gray bars), or phentolamine and terbutaline (PT, light gray bars)
initiated 12 days after adjuvant challenge. (A) IL-4 production was augmented
by treatment with PT over that found in VEH controls. N =8. *p<0.05.
(B) IFN-γ concentrations were higher in TERB- and PT- than with VEH-treated
rats. N =8. *p<0.05; **p<0.01. (C)TNF-α levels were similar in all groups.
N =8. p<0.05. (D) IL-10 secretion was elevated in rats treated with PT over
that seen with VEH treatment. N =8. *p<0.05.
FIGURE 8 | Proliferation of mesenteric lymph node (MLN) cells and IL-2
production. Animals were treated with twice-daily i.p. injections of vehicle
(VEH, black bars), terbutaline (TERB, white bars), phentolamine (PHEN, dark
gray bars), or phentolamine and terbutaline (PT, light gray bars) initiated
12 days after adjuvant challenge. (A) All drug treatments suppressed
proliferation of MLN cells compared with VEH treatment. Horizontal light gray
bar demonstrates non-specific background. (B) IL-2 production did not differ
between treatment groups. N =8. ***p<0.001.
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FIGURE 9 | Cytokine production by mesenteric lymph node (MLN) cells
after 24h of culture. Animals were treated with twice-daily i.p. injections of
vehicle (VEH, black bars), terbutaline (TERB, white bars), phentolamine
(PHEN, dark gray bars), or phentolamine and terbutaline (PT, light gray bars)
initiated 12 days after adjuvant challenge. (A) IL-4 production was comparable
in all groups. N =8. (B) IFN-γ concentrations were lower in PT- than with
VEH-treated rats. N = 8. *p<0.05. (C)TNF-α levels were reduced with TERB
and PT treatment compared with VEH controls. N =8. *p<0.05. (D) IL-10
secretion was suppressed in rats treated with PHEN over that seen with VEH
treatment. N = 8. *p<0.05.
treatment (Figure 9C; p< 0.05); however, PHEN treatment alone
had no effect on TNF-α secretion. In vivo treatment with TERB
did not significantly alter IL-10 production compared with VEH-
treated controls; however, PHEN treatment inhibited IL-10 pro-
duction by MLN cells compared with VEH-treated arthritic rats
(Figure 9D; p< 0.05). There was a trend (p< 0.1) for lower
IL-10 levels in the arthritic rats receiving PT treatment com-
pared with the VEH treatment. IL-10 production in MLN cells
(Figure 9D) from VEH-treated arthritic rats was 17-, 4-, and 4-fold
greater compared with PBMC, spleen, and DLN levels, respectively
(Figures 3D, 5D, and 7D, respectively).
LYMPHOID ORGAN-DEPENDENT EFFECTS OF ADRENERGIC THERAPIES
ON Th1/Th2 CYTOKINE RATIOS
Th1/Th2 cytokine ratio (IFN-γ/IL-4) from the PMBCs did not dif-
fer between arthritic rats treated with TERB or VEH (Figure 10A);
however, treatment with PHEN or PT reduced the Th1/Th2
cytokine ratio compared with VEH-treated rats (p< 0.001). In
contrast, adrenergic drug treatments failed to affect the Th1/Th2
ratio in spleen, DLN or MLN cell cultures compared with arthritic
rats treated with the VEH (Figures 10B–D, respectively).
LYMPHOID ORGAN-DEPENDENT EFFECTS OF ADRENERGIC THERAPIES
ON PRO-INFLAMMATORY/ANTI-INFLAMMATORY CYTOKINE RATIOS
The ratio of pro- to anti-inflammatory cytokine production (TNF-
α/IL-10) in PBMCs and DLN cells revealed that while TERB or
PHEN had minimal effects on the TNF-α/IL-10 ratio, PT treat-
ment significantly reduced the ratio of TNF-α/IL-10 in both cell
populations (p< 0.05, Figures 11A,C). In contrast, spleen cells
from all three adrenergic therapies had reduced TNF-α/IL-10
ratios compared with VEH-treated arthritic rats (Figure 11B;
p< 0.01). Interestingly, treatment with PHEN increased the ratio
of TNF-α/IL-10 over VEH control levels in MLN cell cultures
(Figure 11D; p< 0.05). Finally, there was a trend (p< 0.1) for
reduced TNF-α/IL-10 ratios in the MLN cell cultures following
in vivo TERB or PT treatment.
DISCUSSION
In this study, we confirm and extend our previous findings of the
disease-modifying effects of a β2-AR agonist and/or α-AR antago-
nist treatment in AA after disease onset. Consistent with previous
findings, TERB, PHEN, or PT dramatically ameliorates AA in male
Lewis rats when treatment begins at disease onset (12). Our data
extend these findings to show that all drug treatments suppressed
proliferative responses in cell cultures from all lymphoid tissues
examined. However, IL-2 production is not coupled with pro-
liferation regardless of the adrenergic therapy. Immune cells in
secondary lymphoid organs and peripheral blood are largely non-
responsive to treatment with the β2-AR agonist. These findings
support that the SNS loses its ability to regulate immune cell func-
tions via normal β-AR signal transduction in secondary lymphoid
organs in AA and by extension RA. Importantly, the exceptions
to these findings are the dramatic β2-AR-mediated increase in
spleen cell IL-10 and DLN cell IFN-γ production, respectively.
Surprisingly, treatment with the α-AR antagonist produces greater
changes in cytokine profiles than targeting β2-ARs, suggesting a
shift in the class of AR that predominantly regulates immune func-
tion during chronic disease. In sites not expected to elicit robust
immune responses to CFA challenge (i.e., PBMCs and MLN cells),
PHEN and PT suppresses IFN-γ and TNF-α cytokine production.
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FIGURE 10 | Ratios ofTh1 toTh2 cytokines in secondary immune
compartments. Animals were treated with twice-daily i.p. injections of
vehicle (VEH, black bars), terbutaline (TERB, white bars), phentolamine
(PHEN, dark gray bars), or phentolamine and terbutaline (PT, light gray bars)
initiated 12 days after adjuvant challenge. (A) PBMC: PHEN and PT
treatments lowered the Th1/Th2 cytokine ratio in PBMC cultures compared
with VEH treatment. PT Th1/Th2 cytokine ratios were higher than with
PHEN treatment. N =8. ***p< 0.001. (B) Spleen:Th1/Th2 cytokine ratios
did not differ between AA rats treated with any of the drug treatments
compared with VEH treatment. (C) DLN, similar ratios were found in all
groups. (D) MLN, no differences in Th1/Th2 cytokine ratios were found
between treatment groups.
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FIGURE 11 |TNF/IL-10 ratios in secondary immune compartments.
Animals were treated with twice-daily i.p. injections of vehicle (VEH, black
bars), terbutaline (TERB, white bars), phentolamine (PHEN, dark gray bars), or
phentolamine and terbutaline (PT, light gray bars) initiated 12 days after
adjuvant challenge. (A) PBMC: PT treatments lowered the TNF/IL-10 ratio in
PBMC cultures compared with VEH treatment. N =8. *p<0.05. (B) Spleen:
all drug treatments lowered the TNF/IL-10 ratio compared with VEH treatment.
N =8. **p<0.01. (C) DLN, PT suppressed the TNF/IL-10 ratio compared with
VEH controls. N =8. *p<0.05. (D) MLN, the TNF/IL-10 ratio was greater in
rats treated with PHEN than in VEH controls. N =8. *p<0.08.
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In spleen cells, the major effect of PHEN or PT was to drive IL-10
and suppress TNF-α production. This cytokine profile is expected
to suppress inflammation and drive Th2 responses, which are con-
sistent with improved disease outcome of PHEN or PT treatment.
In contrast to single drug treatments, PT increases IL-4 and IL-10
production in DLN cells, which is expected to suppress inflam-
mation and promote Th2 immunity. This difference in cytokine
profiles may account for PT having the greatest ameliorating effects
on disease, particularly its bone sparing effects.
All adrenergic therapies reduce disease severity. Radiographs
and scoring provide support for a direct and/or indirect effect of
adrenergic drugs on all scoring components used to assess soft tis-
sue swelling (i.e., inflammation) and bone destruction/remodeling
in the arthritic hind-limbs. Direct effects of adrenergic agents
have been reported for both cartilage and bone. Both chondro-
cytes and bone cells (osteoclasts and osteoblasts) express func-
tional ARs (26, 27) and can alter their growth and resorption
activity (28–31). Additionally, immune cells (i.e., macrophages,
T, B, and NK cells) and their products (i.e., TNF-α, IL-1, IFN-
γ, and IL-2) coordinate changes in bone cell function and are
regulated by ARs (32–34). Our findings support direct and/or indi-
rect effects of TERB, PHEN, and PT treatments in ameliorating
inflammation and joint destruction, and indicate these treat-
ments are disease-modifying, anti-rheumatic drugs (DMARDs).
X-ray scores suggest that TERB was more effective at reducing
swelling than either PHEN or PT based on soft tissue assessment,
in agreement with other reports demonstrating β2-AR-mediated
anti-inflammatory effects (35–37). The β2-AR-mediated decrease
in inflammation may be mediated by inhibiting macrophage TNF-
α production and/or reducing reactive oxygen species (35–37).
Surprisingly, PT was much less effective in reducing soft tis-
sue swelling than specifically targeting β2-, or α-ARs. This find-
ing suggests opposing actions of α- and β-ARs in the inflamed
hind limbs. Whether this interaction involves multiple cell types
and/or direct or indirect interplay between α- and β-ARs in the
same cell types is unclear. Provocative new data (38, 39) indi-
cate that β- and α-AR subtypes can form heterodimers that affect
downstream signaling to regulate the inflammatory response.
Similar research is warranted in our model to better under-
stand β- and α-AR-mediated mechanisms regulating soft tissue
swelling.
Immune cells cultured from lymphoid organs of CFA-
challenged rats proliferate ex vivo without any additional immune
challenge, an approach that better mimics the in vivo setting.
Immune cell proliferation was most pronounced in DLNs and
spleen. This finding is consistent with reports of persistent high
antigen load in these tissues (40) and the significant involvement
of both the DLNs and spleen in disease induction and immune
dysregulation during the effector phase of the immune response.
In response to CFA challenge, arthritogenic T cells that can trans-
fer disease to naïve rats are generated in the spleen and DLNs
(41). In agreement with this, we observed the greatest prolifera-
tive responses in DLNs and spleen cells, whereas proliferation was
barely above background in PBMCs and MLN cells. TERB, PHEN,
or PT treatment significantly reduced cellular proliferation in the
spleen, DLN, and MLN, but had no effect on PBMC proliferation.
This is consistent with the normalization of spleen weights after
adrenergic treatments and with secondary lymphoid organs being
sites of lymphocyte clonal expansion.
The reduced proliferative responses with TERB treatment are
also consistent with other studies that demonstrate β2-AR agonists
and norepinephrine treatment reduce proliferation of antigen-
and mitogen-challenged lymphocytes from secondary immune
organs [reviewed in Ref. (21)]. Upon antigen challenge, T cell
proliferation is promoted by the binding of IL-2 to the IL-2R
expressed on T cells [reviewed in Ref. (21)]. Numerous studies
have shown that norepinephrine/epinephrine decrease the pro-
liferative responses in T cells by a β2-AR-mediated reduction in
IL-2 production following mitogen, anti-CD3 antibody, or anti-
gen challenge (21). However, TERB treatment had no significant
effects on IL-2 in our study, despite the β2-AR-mediated reduction
in proliferation. These findings indicate that IL-2 does not drive
the lymphocyte proliferation observed in secondary lymphoid
compartments during the effector phase of AA, and that TERB-
induced decreases in lymphocyte proliferation are not mediated
by IL-2. Reports that chronic secretion of TNF-α can cause IL-2
deficiency at sites of inflammation (42–44) is consistent with our
high TNF levels, low IL-2 production and uncoupling of IL-2-
induced proliferation. Moreover, our findings are consistent with
T cell hyporesponsiveness to T cell receptor (TCR) engagement
(42), with a switch from an IL-2-to-inflammatory-driven immune
response that suppresses IL-2 gene transcription (44). Finally, the
inability of TERB to reduce IL-2 production in spleen and DLN
cells from AA rats is consistent with recent findings from our lab
that β2-ARs are uncoupled from cAMP (18). Others have reported
that IL-2 decreases β-AR density, removing a negative control over
cellular proliferation (45). Similarly, in certain cell populations,
IL-1β can impair β2-AR coupling with adenylate cyclase (46, 47).
Future studies are needed to determine the mechanisms for the
β2-AR-mediated suppression of proliferative responses observed
in secondary lymphoid organs in AA rats.
Surprisingly, treatment with the α-AR antagonist also reduced
lymphocyte proliferation, an effect also observed when com-
bined with TERB. These findings indicate that norepinephrine
interaction with immune cell α- and β-ARs have opposing influ-
ences on lymphocyte proliferation, with α-ARs promoting and
β-ARs opposing lymphocyte expansion during the effector phase
of AA. Studies examining the effects of α-AR agonists on lym-
phocyte proliferation have reported increased, decreased, or no
effect [reviewed in Ref. (48)]. Given the current evidence to date,
lymphocytes express primarily β2-ARs, while innate immune cells
appear to express β2-, α1-, and α2-ARs. Thus, effects of the α-AR
antagonist, PHEN, on lymphocyte proliferation are likely medi-
ated indirectly via α-AR-induced changes in functions of innate
immune cells, such as macrophages, and/or by altering norepi-
nephrine availability through presynaptic α2-ARs. Given the mul-
tiple potential targets of α-AR ligand, the mixed results regarding
α-AR-mediated effects on proliferation is not surprising. Discrep-
ancies regarding the direction of the impact of α-ARs-targeting
drugs on lymphocyte proliferation are likely due to experimental
differences, such as the type of antigen challenge, in vivo or in vitro
drug administration, strain differences, and timing of adminis-
tration relative to immune challenge. Collectively, our findings
support that in contrast to β2-ARs, α-ARs suppress lymphocyte
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cell proliferation during the effector phase of AA, an effect that
is blocked by α-AR antagonists during the effector phase. The
extent to which the effects of TERB, PHEN or PT on proliferative
responses contributes to disease reduction is unclear. However,
inhibition of clonal expansion of arthritogenic T cells would be
expected to reduce disease severity. Future studies will explore this
possibility, as well as, the cell types targeted by these adrenergic
treatments.
In contrast to TERB, PHEN treatment increases the produc-
tion of IL-2 in spleen cells. Interestingly, PT also elevated IL-2 in
DLN cells, but had no effect in other lymphoid compartments. The
importance of these findings for reduced pathology is not clear.
IL-2 is a pleiotropic cytokine. Besides its potent T-cell growth fac-
tor activity, IL-2 is essential for promoting the differentiation of
Th1 (49) and Th2 cells (50). While IL-2 inhibits Th17 (51) and
T follicular helper (Tfh) cell development (52), it does promote
Th17 cell expansion once these cells develop (53). IL-2 is also
involved in activation-induced cell death (AICD), which is impor-
tant for homeostasis and the elimination of potentially harmful
auto-reactive cells, at least in part by a Fas and FasL-dependent
mechanism (54). IL-2 promotes antibody production and prolifer-
ation by B cells (55) and drives the development of CD4+FOXP3+
regulatory T cells (Treg cells), which have suppressor functions and
mediate tolerance (56–58). Thus, IL-2 has broad essential biolog-
ical actions, not only driving T cell proliferation and modulating
effector cell differentiation, but also limiting potentially dangerous
autoimmune reactions. Further research is required to understand
the impact of α- and β-AR-mediated changes in IL-2 production
on disease outcome in our disease model.
Regarding IL-2 and leukocyte proliferation responses, our
findings are consistent with reports of increased SNS activity,
decreased IL-2 production, and reduced proliferative responses
in RA patients. Serum levels of IL-2 are reduced in patients with
active disease, particularly in those with extra-articular mani-
festations (59, 60). Further, in RA patients mitogen-stimulated
PBMCs produce less IL-2 and proliferate less robustly than PBMCs
from controls (59). Low IL-2 and proliferative responses inversely
correlate with disease activity and positively correlate with the
proportion of CD4+ T cells (59), suggesting their importance
in the pathophysiology of RA. Moreover, monocytes may play a
role in regulating IL-2, as their depletion and partial reconstitu-
tion increases IL-2 production and proliferation in RA patients.
Circulating cytokines that are indicators of general immune acti-
vation (including IL-2) increase prior to disease onset in RA
patients (61), consistent with their importance in disease onset.
Our data showing the ability of an α-AR antagonist or com-
bined β2-AR agonist and α-AR antagonist treatment to increase
splenic and DLN IL-2, respectively, indicate the complexity of
regulatory mechanisms for this cytokine by the SNS. IL-2 is
at the “cross-roads” of both effector T-cell responses and tol-
erance [reviewed in Ref. (62)], and the development of lethal
autoimmune disease in IL-2 knock-out mice (63). We have spec-
ulated that this particular cytokine may be the key to explaining
opposite effects of adrenergic agonists on disease severity when
administered prior to vs. after disease onset (12). If this hypoth-
esis is true, then understanding of the mechanisms for these
contradictory effects of adrenergic treatments relative to disease
onset has implications for prevention and therapeutic treatment
of RA.
In the present study, TERB treatment had no effect on IFN-γ
production in spleen, MLN and PBMC, despite the well accepted
role of norepinephrine via β2-ARs to inhibit and enhance the pro-
duction of the Th1 and Th2 cytokines, IFN-γ and IL-4, respectively
(64, 65). The inability of TERB treatment to impact Th cell IFN-γ
and IL-4 production in spleen, MLN, and PBMCs are consistent
with findings by Heijink and coworkers (66) demonstrating that
polarized Th1 and Th2 cells are less responsive to negative feedback
by receptors coupled to the adenylate cyclase/cAMP pathway com-
pared with freshly isolated T cells. Sanders and coworkers (67) also
showed that in freshly isolated CD4+ T cells, a β2-AR agonist could
activate the cAMP pathway to increase IL-2 and IFN-γ, however,
this response is attenuated in differentiated Th1 and Th2 cells. In
these studies, specialized Th subset cells were stimulated by anti-
CD3/anti-CD28 or in vitro differentiation of Th0 cells under Th1
or Th2 polarizing conditions. Similar to the differentiated Th cells,
we also observed that treatment with β2-AR agonists is no longer
able to induce an increase in intracellular cAMP in splenocytes
from arthritic rats 28 days post-adjuvant challenge (18). Further,
lymphocyte β2-ARs in spleen cells from arthritic rats were phos-
phorylated at a site known to induce receptor desensitization. Our
findings are consistent with the loss of control over cytokine pro-
duction by the β2-AR-coupled cAMP pathway in Th effector cells
after CFA challenge. These findings are also consistent with the
differential effects on disease outcome in AA rats when a β-agonist
is administered at different times across the time course of AA.
Thus, differential effects of the agonist after CFA challenge and
after disease onset may be due to targeting of differentiating Th0
cells versus fully differentiated Th cells.
Despite the known inhibitory effects of β2-AR agonists on Th1
cell production of IFN-γ (64, 65), TERB treatment in arthritic
rats elevated IFN-γ production in the DLNs. This finding sug-
gests that β2-AR signaling is not only uncoupled from its normal
cAMP-PKA pathway, but also switches receptor coupling to an
alternate second messenger. Recent findings from our lab indi-
cate that in DLNs, β2-ARs are phosphorylated at a site known to
switch signaling from cAMP to mitogen-activated protein kinase
(MAPK) pathways (18). In AA rats, DLNs drain a site of chronic
inflammation, and thus, are exposed to high concentrations of
inflammatory cytokines. This may explain, in part, the differ-
ent β2-AR responses in spleen and DLN cells. Consistent with
this hypothesis, IL-1β is reported to cause a concentration- and
time-dependent decrease in responses of airway smooth mus-
cle cell and cardiac myocyte to a β-AR agonist that is medi-
ated by uncoupling β-AR from Gs-induced activation of adeny-
lyl cyclase (47, 68, 69). This response was accompanied by an
increase in membrane Gi expression (69), a G-protein coupled
with MAPK activation. The DLNs also receive a much higher
antigen load than other secondary lymphoid organs after base
of the tail CFA challenge. Additionally, the slow release of the
M. butyricum cell wall components from the adjuvant may result
in the persistent sub-optimal challenge in the DLNs. Interest-
ingly, low persistent challenge with environmental adjuvant expo-
sure has been linked to failed tolerance and the development of
autoimmunity (70).
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Neither TERB nor PHEN treatment altered IL-4 production in
any of the tissues compared with VEH-treated arthritic rats. Our
findings are consistent with studies showing that treatment with
either norepinephrine or TERB induces IL-4 production from Th2
clones or Th2 effector cells derived from β2-AR-stimulated naïve
CD4+ T cells (67, 71, 72). In contrast, other studies have shown
that elevations in cAMP were able to increase IL-4 production in
Th2 cells (66). It is unlikely that β2-ARs directly mediate increased
IL-4 production by Th2 cells as the differentiation of Th0 to Th2
cells induces the loss of β2-AR expression (67, 71, 72). Notably, PT
treatment increased IL-4 production in the DLNs. Whether this is
a direct or indirect result of TERB or PHEN, the result of an inter-
action between the two drugs on Th2 cell IL-4 production, or due
to TERB- or PT-induced effects on other immune cell populations
will require additional studies.
The most dramatic effects of PHEN treatment during the
effector phase were the reductions of IFN-γ and IL-2 in the
PBMCs. Since T cells do not normally express α-ARs, the effects
of PHEN or PT on IL-2 or IFN-γ cytokine production could be
indirect. PHEN binding to α2-ARs present in presynaptic ter-
minals is expected to increase availability of norepinephrine for
interaction with T cell β2-ARs. A change in circulating norepi-
nephrine due to spillover from organs that are innervated and
altered epinephrine release from the adrenal medulla could alter
the circulating concentrations of norepinephrine and epineph-
rine. If this occurs, then circulating T cell β2-AR stimulation
could induce changes in T cell cytokines in this compartment.
However, since TERB had no effect on PBMC IFN-γ release, the
decreased IFN-γ production observed following PHEN or PT
treatment is unlikely to be mediated indirectly through presy-
naptic α2-ARs. Alternatively, these treatments could be target-
ing α-ARs expressed in monocytes to alter their production of
cytokines that then induce changes in T cell cytokine produc-
tion. This notion is consistent with a report by Heijnen and
coworkers (73) showing functional α1-ARs in peripheral blood
leukocytes (presumably monocytes) of patients with polyarticular
juvenile RA. Finally, the altered PBMC T cell cytokine produc-
tion observed after PHEN or PT treatment could alter the T cell
subtypes that enters the circulation, increasing subtypes that pro-
duce higher amounts of IFN-γ and IL-2. Mechanisms responsible
for the effects of PHEN treatment on IFN-γ and IL-2 produc-
tion in PBMCs during the effector phase of AA requires further
investigation.
In this study, TERB or PHEN treatment did not alter produc-
tion of the pro-inflammatory cytokine, TNF-α in spleen, lymph
nodes, or PBMCs in arthritic rats after disease onset. This is in
contrast to reports that β2-AR agonists and α-AR antagonists
inhibit macrophage TNF-α production, respectively [reviewed in
Ref. (74–77)]. These findings suggest an impairment of signaling
via both β2- and α-ARs that occurs during the effector phase of
AA. Interestingly, treatment with PT significantly reduced pro-
duction of TNF-α in the spleen, MLN, and PBMCs. It is not
clear why the combination drug treatment reduces TNF-α, in
the absence of effects by the individual treatments, but the find-
ings suggest interactions between β2- and α-AR signaling. Col-
lectively, these findings indicated that SNS signaling to immune
cells via β2- and α-ARs is impaired, or induces alternative second
messengers in monocytes/macrophages in these organs in rats with
established AA.
The greatest effect of TERB and/or PHEN on cytokine produc-
tion was observed for splenic IL-10 production, where all three
adrenergic treatments induced a significant increase in IL-10 pro-
duction. This finding is consistent with the known effects of β2-AR
agonists and α-AR antagonists to increase IL-10 production (78,
79). The combination treatment increased IL-10 production to
the same extent as treatment with each drug alone, suggesting that
the effects of each of the components were neither additive nor
synergistic. Thus, at least in the spleen, these receptors are capable
of inducing production of second messengers, despite the lack of
AR-induced responses for TNF-α production. In DLNs, IL-10 pro-
duction increased significantly only after treatment with combined
TERB and PHEN, although there was a trend for increased IL-10
with each individual adrenergic drug. We observed no effect for
any of the adrenergic treatments in IL-10 production by PBMCs.
In contrast, PHEN significantly reduced IL-10 levels in the MLNs,
an effect that is inconsistent with reports that α-AR agonists sup-
press IL-10 production (78). Thus, the pattern of IL-10 production
after adrenergic treatments was dependent upon the secondary
lymphoid tissue examined.
Data supports that sympathetic dysfunctions significantly alter
the balance between Th1-Th2 cell differentiation in RA (18, 80).
RA is dominated by a Th1 response with selective accumulation of
Th1 cells within the synovial compartment (81). RA and juvenile
chronic arthritis co-exist with chronically elevated sympathetic
activity [reviewed in Ref. (8)]. We and others have demonstrated
that sympathetic innervation of the lymphoid organs in arthritic
rodents (14, 15) and in arthritic joints of RA patients (17, 82)
are lost and/or reorganized. Indeed, in this study, treatment with
a β2-AR agonist fails to shift T lymphocyte cytokine responses
toward a Th2 profile in any of the secondary lymphoid organs
of AA rats. However, in vivo treatment with the α-AR antagonist
shifts the ex vivo cytokine profile from Th1 to a Th2 response,
indicating that α-AR stimulation inhibits this shift. These findings
are consistent with a recent report showing that catecholamines
fail to shift T cell cytokines from a Th1 to a Th2 profile in
PBMCs from RA patients, as seen in healthy donors (83). Thus,
impaired sympathetic functioning is intimately linked with disease
pathology.
Stimulating β2-ARs and/or blocking α-ARs reduces the ratio
of pro-to-anti-inflammatory cytokine production by PBMCs,
spleen, and DLN cells. The reduced pro-to-anti-inflammatory
cytokine ratios are consistent with the well-known effects of
β2-AR stimulation or α-AR blockade to inhibit TNF-α and pro-
mote IL-10 production in macrophages and dendritic cells (74–
79). Spleen cells displayed the greatest drug-induced changes in
anti-inflammatory profiles, largely due to greater IL-10 produc-
tion. In contrast, TERB or PHEN treatment, tend to induce an
anti-inflammatory secretory profile in PBMCs and DLN cells.
However, dual drug treatment that augment β2- and dampen α-
AR activation-induced anti-inflammatory profiles. These changes
were due to reduced TNF-α secretion in PBMCs and increased
IL-10 in DLN cells. Therefore, TERB, PHEN, or PT-induced
anti-inflammatory profiles may be responsible, at least in part,
for improved disease outcomes in our study.
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Interestingly, PHEN treatment induced a pro-inflammatory
cytokine profile in MLN cells, an effect due to lower IL-10 in
the absence of an effect on TNF-α production. Beta2-AR stimu-
lation inhibited TNF-α secretion, but was unable to significantly
reduce the pro-to-anti-inflammatory ratio. Thus, blocking α-AR
activation in the MLNs had an opposing effect on IL-10 produc-
tion to that seen in the spleen. The reason for this difference may
lie in the cellular source of IL-10 in these immune organs, but
requires further investigation. Moreover, our data suggest that acti-
vation of either α- or β-ARs have anti-inflammatory effects in the
MLNs. Why our drug treatments differentially affected inflamma-
tory drive depending on the specific lymphoid tissue is unclear
and warrants further study. Perhaps these differences reflect the
unique functions of each lymphoid organ/tissue in response to
the CFA challenge and the site of injection. The primary function
of DLNs is to respond to the intradermal challenge, whereas the
spleen participates in the systemic response. As part of the systemic
response in AA, the spleen filters the blood, and is a major source
of arthritogenic T cells that infiltrate affected joints. In contrast,
the blood serves as a conduit for trafficking cells of the immune
system. Finally, the MLNs are most responsive to antigens that
travel in lymphatic vessels from the gut. Collectively, our findings
indicate that the SNS maintains the ability to inhibit (via β2-ARs)
or promote (via α-ARs) inflammation in PBMCs, splenocytes, and
DLN cells, but not in MLN cells.
Body weights are reduced 28 days after disease induction. This
finding concurs with the well-documented AA-, CIA- and RA-
induced cachexia (loss of body mass without altered diet or
increased activity) due to inflammation that causes hypermeta-
bolic protein and fat breakdown, skeletal muscle wasting, and to
a lesser extent, lost white adipose tissue mass (12, 84–86). More-
over, treatment with PHEN, TERB, or PT significantly reduced
disease-associated cachexia. The significance of these findings is
underscored by cachexia occurring in ~2/3rds of all RA patients,
and is a major contributor in greater morbidity and mortality in
RA patients (84, 87, 88). Here, we did not monitor food intake,
but other studies have shown that this factor is not contribu-
tory to disease-induced weight loss (89). However, inflammation
indirectly reduces cellular mass by protein breakdown due to acti-
vation of the ubiquitin–proteasome pathway (90) and lipolysis
(86). These effects are mediated at least in part by TNF-α (91).
Adrenergic therapies in our study suppresses ex vivo TNF-α pro-
duction and the pro- to anti-inflammatory ratios in a treatment-
and immune organ-specific manner, consistent with a role for
inflammation in rheumatoid cachexia.
In summary, it is clear that the critical functions of the SNS
to regulate lymphocyte proliferation, Th1/Th2 cell differentiation,
and inflammation are impaired/altered in AA rats, due to altered
β2- and α-AR functions. Selective α-AR blockade and/or β-AR
activation in AA suppresses ex vivo proliferation, but is indepen-
dent of sympathetic regulation of IL-2 production in AA. This is
true in all immune organs examined, except PBMCs, and is con-
sistent with the function of blood as a conduit for immune cell
trafficking. Adrenergic treatments affect Th1/Th2 cytokines dif-
ferently in every tissue examined in AA, perhaps reflecting the
different immune functions of each organ. Most striking was
the β2-AR-mediated increase in IFN-γ in the DLNs and lack
of a β2-AR-mediated effect on IFN-γ in the spleen, particularly
since arthritogenic T cells are generated at both sites (92, 93).
Regardless of these differences, the overall outcome is a failure
to drive Th2-type cytokine expression via β2-AR stimulation,
and thus, loss of a negative feedback mechanism for regulating
cellular immunity. These findings are consistent with reports of
disease-induced elevation in sympathetic tone (8), and high nor-
epinephrine concentration-dependent β2-AR down-regulation,
desensitization, and/or shifts in G-protein coupling (18, 82, 94,
95). Indeed, we have previously discovered differences in phos-
phorylation of β2-ARs in DLN and spleen cells collected from
AA rats that may explain the IFN-γ findings in this study (18).
Further, essential SNS regulation of innate immunity, via β2- and
α-ARs, is also impaired as demonstrated, with inability of β2-AR
stimulation or α-AR blockade to reduce TNF-α and increase IL-10
production in DLN cells. Stimulation of β2-ARs similarly fails to
reduce TNF-α production in the spleen cells.
Collectively, our findings indicate disrupted β2-ARs, but not
α-ARs signaling in AA, which consequently derails sympathetic
regulation of lymphocyte expansion, Th cell differentiation, and
inflammation required for immune system homeostasis. The clin-
ical relevance of our findings is several-fold. First, they underscore
the complexity of the disease’s relevant immune functions, their
regulation by the SNS and the limitations of peripheral blood
to decipher complex pathology. Secondly, distinct differences in
SNS-immune interactions in spleen and lymph nodes likely reflect
functional and microenvironmental differences of these immune
organs, which currently are under appreciated and sources of dis-
crepancies, inconsistencies, and confusion in the literature. Thus,
relevant animal models for RA and novel approaches are required
to elucidate both immune and neural-immune mechanisms in dis-
ease pathology. Finally, disease-modifying and suppressive inflam-
matory effects of targeting β2- and α-ARs strongly support that
combined AR-targeted therapies have great therapeutic potential
to reduce joint destruction and inflammation and complications
of RA, like cachexia. While promising, a greater understanding
of the mechanisms by which these beneficial effects are realized
is essential to evaluate therapeutic potential and guide clinical
applications.
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